

RealRate

PHARMACEUTICAL 2020

Xencor Inc Rank 18 of 358









RealRate

PHARMACEUTICAL 2020

Xencor Inc Rank 18 of 358



The relative strengths and weaknesses of Xencor Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xencor Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Xencor Inc is the variable Intangible Assets, reducing the Economic Capital Ratio by 2.4% points.

The company's Economic Capital Ratio, given in the ranking table, is 281%, being 244% points above the market average of 36%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 558,405 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 14,421 |
| Liabilities, Current | 66,558 |
| Liabilities, Non-Current | 10,491 |
| Other Assets | 81,619 |
| Other Compr. Net Income | 2,132 |
| Other Expenses | 312 |
| Other Liabilities | 0 |
| Other Net Income | 13,363 |
| Other Revenues | 156,700 |
| Property and Equipment | 15,805 |
| Research and Development | 118,590 |
| Selling, General and Administrative Expense | 24,286 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 670,250 |
| Liabilities | 77,049 |
| Expenses | 143,188 |
| Revenues | 156,700 |
| Stockholders Equity | 593,201 |
| Net Income | 26,875 |
| Comprehensive Net Income | 27,941 |
| Economic Capital Ratio | 281% |

